Similar articles

• Skin metabolism and transdermal absorption of viprostol, a synthetic PGE2 analog, in the rat: effect of vehicle.

  Nicolau G, Dahlin DC, Kohlbrenner M, Chan PS, Ronsberg MA, Saunders TK, Yacobi A, Cervoni P. Nicolau G, et al. Skin Pharmacol. 1989;2(1):22-9. doi: 10.1159/000210798. Skin Pharmacol. 1989. PMID: 2627412
• Pre-systemic metabolism of viprostol in the monkey following oral and topical administration.

  Nicolau G, Tonelli AP, Cosulich DB, Perkinson NA, DiCioccio AT, McWilliams WE, Yacobi A. Nicolau G, et al. Xenobiotica. 1988 Jul;18(7):797-802. doi: 10.3109/00498258809041718. Xenobiotica. 1988. PMID: 3176518
• Deposition of viprostol (a synthetic PGE2 vasodilator) in the skin following topical administration to laboratory animals.

  Nicolau G, Baughman RA, Tonelli A, McWilliams W, Schiltz J, Yacobi A. Nicolau G, et al. Xenobiotica. 1987 Sep;17(9):1113-20. doi: 10.3109/00498258709044210. Xenobiotica. 1987. PMID: 3120427
• Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models.

  Godin B, Touitou E. Godin B, et al. Adv Drug Deliv Rev. 2007 Sep 30;59(11):1152-61. doi: 10.1016/j.addr.2007.07.004. Epub 2007 Aug 16. Adv Drug Deliv Rev. 2007. PMID: 17889400 Review.
• Skin metabolism in transdermal therapeutic systems.

  Hikima T, Tojo K, Maibach HI. Hikima T, et al. Skin Pharmacol Physiol. 2005 Jul-Aug;18(4):153-9. doi: 10.1159/000085860. Epub 2005 May 20. Skin Pharmacol Physiol. 2005. PMID: 15908755 Review.